Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, and inflammation in cyclosporine a-induced gingival enlargement: A pilot in vitro study using a three-dimensional model of the human oral mucosa

Journal of Periodontology

Volumn 84, Issue 5, 2013, Pages 634-640

  Johanson, Matthew ^a   Zhao, Xiang R ^a   Huynh Ba, Guy ^a   Villar, Cristina C ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Collagen; Cyclosporine; Gingival overgrowth; Inflammation; Metalloproteases; Tissue inhibitor of metalloproteinases

Indexed keywords

CYCLOSPORIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; SIGNAL PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANALYSIS OF VARIANCE; ARTICLE; AUDIOVISUAL EQUIPMENT; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; ENZYMOLOGY; GINGIVA; GINGIVA OVERGROWTH; HUMAN; INFLAMMATION; METABOLISM; MOUTH MUCOSA; NONPARAMETRIC TEST; PILOT STUDY; SECRETION (PROCESS);

ANALYSIS OF VARIANCE; CELLS, CULTURED; CYCLOSPORINE; EXTRACELLULAR MATRIX PROTEINS; GINGIVA; GINGIVAL OVERGROWTH; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASES; MODELS, ANATOMIC; MOUTH MUCOSA; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84877115439     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2012.120224     Document Type: Article

References (44)

1. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323-1327.
2. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991;52:53-57.
3. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981;305: 266-269.
4. Bolman RM 3rd, Elick B, Olivari MT, Ring WS, Arentzen CE. Improved immunosuppression for heart transplantation. J Heart Transplant 1985;4:315-318.
5. Seydoux C, Stumpe F, Hurni M, et al. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients. Transplant Proc 1998;30:4037-4043.
6. Farooqui AN, Ahmad SL, Mansuri FA. Efficacy of cyclosporin-A in refractory rheumatoid arthritis. J Coll Physicians Surg Pak 2004;14:139-141.
7. Hetland ML, Stengaard-Pedersen K, Junker P, et al CIMESTRA Study Group. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-1409.
8. Shintani Y, Kaneko N, Furuhashi T, Saito C, Morita A. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis. J Dermatol 2011;38:966-972.
9. Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: Results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011;38:2466-2474.
10. Boltchi FE, Rees TD, Iacopino AM. Cyclosporine A-induced gingival overgrowth: A comprehensive review. Quintessence Int 1999;30:775-783.
11. Tipton DA, Stricklin GP, Dabbous MK. Fibroblast heterogeneity in collagenolytic response to cyclosporine. J Cell Biochem 1991;46:152-165.
12. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 1999;21: 176-196.
13. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
14. Schincaglia GP, Forniti F, Cavallini R, Piva R, Calura G, del Senno L. Cyclosporin-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 1992;21:181-185.
15. Kinane DF. Regulators of tissue destruction and homeostasis as diagnostic aids in periodontology. Periodontol 2000 2000;24:215-225.
16. Zebrowski EJ, Pylypas SP, Odlum O, Johnson RB. Comparative metabolism of 3H-glucosamine by fibroblast populations exposed to cyclosporine. J Periodontol 1994;65:565-567.
17. Dannewitz B, Edrich C, Tomakidi P, et al. Elevated gene expression of MMP-1, MMP-10, and TIMP-1 reveal changes of molecules involved in turn-over of extracellular matrix in cyclosporine-induced gingival overgrowth. Cell Tissue Res 2006;325:513-522.
18. Bolzani G, Della Coletta R, Martelli Jú nior H, Martelli Jú nior H, Graner E. Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. J Periodontal Res 2000;35:51-58.
19. Cotrim P, Martelli-Junior H, Graner E, Sauk JJ, Coletta RD. Cyclosporin A induces proliferation in human gingival fibroblasts via induction of transforming growth factor-b1. J Periodontol 2003;74:1625-1633.
20. Hyland PL, Traynor PS, Myrillas TT, et al. The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. J Periodontol 2003;74:437-445.
21. Dannewitz B, Tomakidi P, Syagailo Y, et al. Elevation of collagen type I in fibroblast-keratinocyte cocultures emphasizes the decisive role of fibroblasts in the manifestation of the phenotype of cyclosporin A-induced gingival overgrowth. J Periodontal Res 2009;44:62-72.
22. Sukkar TZ, Thomason JM, Cawston TE, et al. Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines. J Periodontal Res 2007;42:580-588.
23. Daley TD, Wysocki GP, Day C. Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62: 417-421.
24. McGaw WT, Porter H. Cyclosporine-induced gingival overgrowth: An ultrastructural stereologic study. Oral Surg Oral Med Oral Pathol 1988;65:186-190.
25. Fu E, Nieh S, Wikesjo UM. The effect of plaque retention on cyclosporine-induced gingival overgrowth in rats. J Periodontol 1997;68:92-98.
26. Guo J, Wang W, Yao L, Yan F. Local inflammation exacerbates cyclosporine A-induced gingival overgrowth in rats. Inflammation 2008;31:399-407.
27. Thomas DW, Newcombe RG, Osborne GR. Risk factors in the development of cyclosporine-induced gingival overgrowth. Transplantation 2000;69:522-526.
28. Thomason JM, Seymour RA, Ellis JS. Risk factors for gingival overgrowth in patients medicated with ciclosporin in the absence of calcium channel blockers. J Clin Periodontol 2005;32:273-279.
29. de Oliveira Costa F, Diniz Ferreira S, de Miranda Cota LO, da Costa JE, Aguiar MA. Prevalence, severity, and risk variables associated with gingival overgrowth in renal transplant subjects treated under tacrolimus or cyclosporin regimens. J Periodontol 2006;77:969-975.
30. Dongari-Bagtzoglou A, Kashleva H. Development of a highly reproducible three-dimensional organotypic model of the oral mucosa. Nat Protoc 2006;1:2012-2018.
31. Mariani G, Calastrini C, Carinci F, Marzola R, Calura G. Ultrastructural features of cyclosporine A-induced gingival hyperplasia. J Periodontol 1993;64:1092-1097.
32. Loichot C, Bentue-Ferrer D, Bernard N, et al. Therapeutic Drug Monitoring Group of the French Pharmacological Society. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. Fundam Clin Pharmacol 2006;20:91-96.
33. Saunders WB, Bayless KJ, Davis GE. MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 2005;118:2325-2340.
34. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-A and TGF-b. J Cell Sci 2005;118: 2143-2153.
35. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membranetype-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002;115:3427-3438.
36. Hefti AF, Eshenaur AE, Hassell TM, Stone C. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J Periodontol 1994;65:744-749.
37. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporin-A. Br Dent J 1984;157:305-309.
38. Margiotta V, Pizzo I, Pizzo G, Barbaro A. Cyclosporinand nifedipine-induced gingival overgrowth in renal transplant patients: Correlations with periodontal and pharmacological parameters, and HLA-Antigens. J Oral Pathol Med 1996;25:128-134.
39. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporin on some gingival health parameters of renal transplant patients. A longitudinal study. J Clin Periodontol 1987;14:610-613.
40. Heasman PA, Collins JG, Offenbacher S. Changes in crevicular fluid levels of interleukin-1 beta, leukotriene B4, prostaglandin E2, thromboxane B2 and tumour necrosis factor alpha in experimental gingivitis in humans. J Periodontal Res 1993;28:241-247.
41. Chaudhari AU, Byakod GN, Waghmare PF, Karhadkar VM. Correlation of levels of interleukin-1b in gingival crevicular fluid to the clinical parameters of chronic periodontitis. J Contemp Dent Pract 2011;12:52-59.
42. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
43. Murphy G, Bretz U, Baggiolini M, Reynolds JJ. The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes. Biochem J 1980; 192:517-525.
44. Ilumets H, Rytila P, Demedts I, et al. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2007;2:369-379.